Abstract
Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Current Gene Therapy
Title: Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases
Volume: 4 Issue: 3
Author(s): M. Azzouz and N. Mazarakis
Affiliation:
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Abstract: Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Export Options
About this article
Cite this article as:
Azzouz M. and Mazarakis N., Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346291
DOI https://dx.doi.org/10.2174/1566523043346291 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Patents Relating to the Application of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell and Whole Marrow Transplantation for Neurodegenerative Diseases: A Review
Recent Patents on Regenerative Medicine Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets